Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published: September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like Why hypoglycemia-induced glucagon secretion becomes impaired in diabetes September 27, 2024 Ending emergency food benefits linked to higher child maltreatment rates October 29, 2026 Local Med-tech Company, Bedfont Scientific Ltd., Celebrates Double Triumph at the KICC Awards November 28, 2023
Local Med-tech Company, Bedfont Scientific Ltd., Celebrates Double Triumph at the KICC Awards November 28, 2023